Royalty Pharma plc
RPRX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $2.38B | $2.26B | +5.1% |
| Operating income | $1.56B | $1.29B | +20.7% |
| Net income | $771M | $859M | −10.2% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $690M | $609M | +13.3% |
| Operating income | $411M | $427M | −3.8% |
| Net income | $145M | $284M | −49.1% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Royalty Pharma's revenue in FY2025?
- $2.38B in FY2025 (Fiscal year ended Dec 31, 2025), +5.1% vs $2.26B a year earlier, per its 10-K filed Feb 2026.
- Was Royalty Pharma profitable in FY2025?
- Yes: net income was $771M and operating income $1.56B in FY2025.
- What was Royalty Pharma's revenue in Q3 2026?
- $690M (+13.3% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.